Diagnosis and Detection of Pancreatic Cancer

Chu, Linda C.; Goggins, Michael; Fishman, Elliot K.

doi:10.1097/ppo.0000000000000290

Cited by 251 publications

(200 citation statements)

References 82 publications

Supporting

Mentioning

192

Contrasting

Unclassified

Order By: Relevance

“…Cross‐sectional imaging alone, including CT and/or magnetic resonance imaging (MRI), was used for preoperative diagnostic evaluation in 15 children in our study. MRI is often used in children due to the risks of radiation exposure with high‐resolution CT and better tissue characterization to detect occult lesions 8–10 . EUS biopsy ( n = 18) was most commonly used for preoperative diagnostic evaluation in our study.…”

Section: Discussionmentioning

confidence: 96%

Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study

Vasudevan

Zhu

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background To better characterize short‐term and long‐term outcomes in children with pancreatic tumors treated with pancreaticoduodenectomy (PD). Methods Patients 21 years of age or younger who underwent PD at Pediatric Surgical Oncology Collaborative (PSORC) hospitals between 1990 and 2017 were identified. Demographic, clinical information, and outcomes (operative complications, long‐term pancreatic function, recurrence, and survival) were collected. Results Sixty‐five patients from 18 institutions with a median age of 13 years (4 months‐22 years) and a median (IQR) follow‐up of 2.8 (4.3) years were analyzed. Solid pseudopapillary tumor of the pancreas (SPN) was the most common histology. Postoperative complications included pancreatic leak in 14% (n = 9), delayed gastric emptying in 9% (n = 6), marginal ulcer in one patient, and perioperative (30‐day) death due to hepatic failure in one patient. Pancreatic insufficiency was observed in 32% (n = 21) of patients, with 23%, 3%, and 6% with exocrine, or endocrine insufficiencies, or both, respectively. Children with SPN and benign neoplasms all survived. Overall, there were 14 (22%) recurrences and 11 deaths (17%). Univariate analysis revealed non‐SPN malignant tumor diagnosis, preoperative vascular involvement, intraoperative transfusion requirement, pathologic vascular invasion, positive margins, and need for neoadjuvant chemotherapy as risk factors for recurrence and poor survival. Multivariate analysis only revealed pathologic vascular invasion as a risk factor for recurrence and poor survival. Conclusion This is the largest series of pediatric PD patients. PD is curative for SPN and benign neoplasms. Pancreatic insufficiency is the most common postoperative complication. Outcome is primarily associated with histology.

show abstract

Section: Discussionmentioning

confidence: 96%

Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study

Vasudevan

Zhu

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Yet, the two meta-analyses evaluating colorectal cancer (including 5 different studies) did not find strong support for an association [22,23], although 2 more studies have been published since showing a significantly increased risks [24,25]. For pancreatic cancer, the 12th most common cancer type, with only 8% 5-year survival [26], we have identified 6 case-control studies [27][28][29][30][31][32] and 1 cohort study [33] of which 3 studies clearly show statistically increased risks (up to 9-times higher than non-users) [27,29,30]. Yet, methodological heterogeneity and selection bias may challenge the interpretation of these findings.…”

Section: Introductionmentioning

confidence: 98%

Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden

2019

View full text Add to dashboard Cite

Background The long-term safety of proton pump inhibitors (PPIs) is increasingly questioned. The aim of our study was to assess the risk of pancreatic cancer among longterm PPI users in Sweden. Methods This population-based nationwide Swedish cohort study including 796,492 adult long-term PPI users has been used to calculate the standardized incidence rate ratios (SIRs) and 95% confidence intervals (CI) for pancreatic cancer, stratifying by indications of use, age, sex, and duration of use. The risk among all 20,210 long-term H2-receptor antagonist users was assessed as comparison.Results Pancreatic cancer was found in 1733 long-term PPI users, and 25 H2-receptor antagonist users. For PPI users, the risk of pancreatic cancer was increased overall (SIRs = 2.22; 95% CI 2.12-2.32) and in all subgroup analyses, with the highest risk among PPI-users younger than 40 years (SIR = 8.90,, and among individuals with a history of Helicobacter pylori (SIR = 2.99, 95% CI 2.54-3.49). After the first year after enrolment (during which PPI use may be because of early symptoms of pancreatic cancer), the risk remained increased over time, with SIR = 1.57 (95% CI 1.38-1.76) after 5 years. No associations were found for H2-receptor antagonists (SIR = 1.02, 95% CI 0.66-1.51). Conclusions This large study showed an increased risk of pancreatic cancer in long-term users of PPIs in Sweden, in particular among the youngest users.

show abstract

“…PDA is a highly aggressive malignancy with limited treatment options and a dismal prognosis. PDA represents the fourth leading cause of cancer death worldwide, and the 12th most common cancer in the world [6,7]. The detrimental outcome is related to delayed diagnosis, often a consequence of non-specific symptoms such as abdominal pain, jaundice and weight loss.…”

Section: Epidemiology and Clinical Outcome Of Pdamentioning

confidence: 99%

Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies

Pereira

Chio

2019

Genes

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is an extremely aggressive disease with a high metastatic potential. Most patients are diagnosed with metastatic disease, at which the five-year survival rate is only 3%. A better understanding of the mechanisms that drive metastasis is imperative for the development of better therapeutic interventions. Here, we take the reader through our current knowledge of the parameters that support metastatic progression in pancreatic ductal adenocarcinoma, and the experimental models that are at our disposal to study this process. We also describe the advantages and limitations of these models to study the different aspects of metastatic dissemination.

show abstract

Diagnosis and Detection of Pancreatic Cancer

Cited by 251 publications

References 82 publications

Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study

Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study

Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden

Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies

Contact Info

Product

Resources

About